Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe bullous pemphigoid. The data were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology, AAD, Annual Meeting. BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin and painful lesions. The ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg every two weeks after an initial loading dose or placebo added to standard-of-care oral corticosteroids, OCS. During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.